Kalvebod Brygge 43
Copenhagen 1560
Denmark
45 70 20 27 28
https://www.genmab.com
Sektor(en):
Branche:
Vollzeitmitarbeiter: 1.445
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, Pres & CEO | 2,39M | N/A | 1961 |
Mr. Anthony Pagano | Exec. VP & CFO | 711,5k | N/A | 1978 |
Mr. Anthony Mancini | Exec. VP & COO | 1,29M | N/A | 1971 |
Dr. Judith V. Klimovsky M.D. | Exec. VP & Chief Devel. Officer | 903,06k | N/A | 1958 |
Dr. Tahamtan Ahmadi | Exec. VP, Chief Medical Officer & Head of Experimental Medicines | 738,87k | N/A | 1973 |
Dr. Mijke Zachariasse Ph.D. | Director of Protein Production & Chemist and Non-Independent Director | 123,14k | N/A | 1974 |
Dr. Rima Bawarshi Nassar Ph.D. | VP, Head of Global Regulatory Affairs Oncology & Non-Independent Director | 109,46k | N/A | 1953 |
Mr. Peter Ros | Sr. Director of Fin. & Accounting | N/A | N/A | N/A |
Mr. Andrew Carlsen | Sr. Director, VP & Head of Investor Relations | N/A | N/A | N/A |
Ms. Birgitte Stephensen M.Sc. | Exec. VP & Chief Legal Officer | N/A | N/A | 1961 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/Ss ISS Governance QualityScore, Stand 31. Juli 2022, lautet 1. Die grundlegenden Scores sind Audit: 2, Vorstand: 1, Shareholderrechte: 1, Kompensation: 5.